Best NAD+ in Canada (2026)
November 18, 2026Creatine for Women’s Brains: 28 Days to a Sharper Mind?
November 19, 2026Quick Summary
A brand-new review pulled together every randomized trial of NAD+ and its precursors in people with heart failure — four trials, 387 patients — and the answer was flat: no real improvement in heart function, hospital stays, or survival. The only result that reached statistical significance was a small rise in creatinine, a kidney marker, in the supplement groups. It is the second big letdown for NAD+ boosters in six weeks — and it punctures the idea that topping up NAD+ is a shortcut to a healthier heart.
For years, NAD+ boosters have been sold as cellular fuel — capsules that top up a molecule your body uses for energy and DNA repair. The pitch is seductive, and the price tags are not small. But when researchers pooled the trials in people whose hearts were actually failing, the boosters did not move a single meaningful number.
| Topic | What the research shows |
|---|---|
| Tested | Intravenous NAD+ or oral nicotinamide riboside (NR) versus placebo, on top of standard heart failure treatment |
| The evidence | Systematic review and meta-analysis of 4 randomized controlled trials, 387 adults with symptomatic heart failure |
| Heart function | No significant change in ejection fraction (LVEF) at 1 month, 3 months, or last follow-up |
| Hospital stays and survival | No significant reduction — hospitalization risk ratio 0.63, mortality risk ratio 0.51, neither statistically significant |
| The wrinkle | Serum creatinine rose significantly with NAD+ (up 7.46 μmol/L), a kidney marker worth watching |
Four trials, 387 patients, one flat result
The review, published November 17 in the European Journal of Clinical Pharmacology, searched five major databases for every randomized trial of NAD+ or its precursors in adults with symptomatic heart failure, through September 2025. Only four trials qualified, with 387 patients between them. Everyone was already on standard heart failure therapy — the supplement was an add-on, not a replacement.
Here is what the pooled numbers actually say:
| Outcome | What happened |
|---|---|
| Heart failure hospitalization | Risk ratio 0.63 across 268 patients — 37% lower on paper, but the confidence interval (0.36–1.09) crosses 1.0 and P=.10, so it is not statistically significant |
| Death from any cause | Risk ratio 0.51 across 238 patients, but with a very wide confidence interval (0.09–2.86) and P=.45 — not significant |
| Ejection fraction (LVEF) | +2.10% at 1 month (P=.07), −0.48% at 3 months (P=.83), +1.54% at last follow-up (P=.18) — none significant |
| NT-proBNP | Down 383 pg/mL on average, but P=.29 — not significant |
| Creatinine | Up 7.46 μmol/L, P=.005 — the only statistically significant result, and not a good one |
The creatinine wrinkle deserves a closer look
Creatinine is a waste product your muscles make every day, and your kidneys filter it out of the blood. When blood creatinine rises, it can mean the kidneys are working harder. The rise seen here, 7.46 μmol/L, is small in absolute terms — but it was consistent enough across 209 patients to be statistically significant (P=.005), and the review’s authors singled it out as warranting further evaluation.
To be fair, a small creatinine bump is not proof of kidney damage. It could partly reflect changes in muscle metabolism rather than kidney function, and the trials were short. The liver enzyme ALT did not change, and the interventions were described as generally well tolerated in the short term. Still, it is a strange look for a supplement sold on cellular health: the one clear signal pointed the wrong way.
Déjà vu: NAD+ boosters keep missing when the trials get big
If this result feels familiar, it should. Six weeks ago, we covered the NOPARK trial, the first large, year-long test of nicotinamide riboside in early Parkinson disease: 410 adults, 1,000 mg of NR a day for 52 weeks. The outcome was worse than flat — the supplement group’s symptom scores worsened slightly more than placebo’s, and mood, sleep, and digestion complaints worsened more with NR too.
Put the two together and a pattern emerges. Small, early studies and lab markers made NAD+ boosters look like a breakthrough. The bigger, longer, harder trials — the ones that measure what actually happens to people — keep landing flat. That does not mean the idea is dead: four small trials cannot settle the question for good, and the review’s authors call for larger, longer-term trials. But the burden of proof has flipped. The people selling certainty about NAD+ are now the ones who need to produce it.
One Canadian note: NR and NAD+ capsules are sold here as natural health products, and licensed ones carry an eight-digit NPN on the label. IV NAD+ drips are a different world — clinic-administered, expensive, and not something you buy off a shelf. The trials in this review tested both forms, and neither delivered.
What is NAD+ and how are NAD+ boosters supposed to work?
NAD+ — short for nicotinamide adenine dinucleotide — is a coenzyme found in every cell. More than 400 enzymes need it to do their jobs. Your body makes it from niacin (vitamin B3) and the amino acid tryptophan, and it helps turn food into energy, repair DNA, and send signals between cells.
The sales pitch goes like this: NAD+ levels fall as we age, and topping them back up restores youthful cell function. They come in three main forms. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are precursors — raw materials your body converts into NAD+. Plain NAD+ capsules are the third, but there is a catch: when NAD+ is swallowed, the gut breaks it down into nicotinamide before absorbing it, so the molecule itself never reaches your cells intact. IV NAD+ skips the gut entirely, which is why clinics charge hundreds of dollars a session for it.
What are the side effects of NAD+ boosters?
In the trials so far, NR and NMN have been fairly well tolerated. In the year-long NOPARK trial, overall side-effect rates matched placebo, and serious adverse events were actually less common in the NR group. The new flag from the heart failure review is the creatinine rise — small, but real enough to watch, especially if your kidneys are a concern.
It helps to keep the B3 family straight, because the side effects differ by form. Nicotinic acid — the form of niacin used for cholesterol — causes skin flushing in most people at doses of 30 to 50 mg or more. Nicotinamide and NR do not cause flushing. But high doses of nicotinamide, around 3,000 mg a day, have been linked to nausea, vomiting, and signs of liver toxicity. People with kidney or liver issues, anyone who is pregnant or nursing, and anyone taking prescription medication should talk to a clinician first.
How much NAD+ booster should you take?
There is no official recommended dose of NR or NMN for any purpose. The best-studied regimen is the one from NOPARK: 1,000 mg of NR a day for a full year. For scale, the daily requirement for vitamin B3 itself is tiny — 16 mg for adult men and 14 mg for women — so research doses run dozens of times higher than what your body needs for basic nutrition.
The official upper limit for supplemental niacin is 35 mg a day, but that number is based on flushing from nicotinic acid and does not map neatly onto NR, which is sold as a different compound. That gap is part of the problem: people take doses far beyond any established safety threshold for the vitamin family, on the strength of marketing rather than long-term safety data. And the NOPARK lesson stands: more is not better. A full year of 1,000 mg a day did not just fail to help — the supplement group went the wrong way on the main scale. Follow the product label and resist the urge to megadose.
What should you look for on the label?
First, a valid NPN — an eight-digit number on the label means the product is licensed as a natural health product in Canada. Second, the right form: look for “nicotinamide riboside” (often sold as the chloride salt) or “NMN” spelled out — not plain niacin or nicotinamide, which are different compounds. Third, third-party testing, and a label that states the actual dose per capsule rather than hiding it in a proprietary blend. Beware of any product promising to treat, reverse, or prevent heart disease: that is not a legal claim for a natural health product.
References
- Hamzah, K. A., et al. (2026). Impact of exogenous nicotinamide adenine dinucleotide and its precursors supplementation in adults with heart failure: A systematic review and meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology, 82(12), 295. https://pubmed.ncbi.nlm.nih.gov/43040090/
- Brakedal, B., et al. (2026). Nicotinamide riboside for patients with early-stage Parkinson disease: The NOPARK randomized clinical trial. JAMA, 336(19), 1723–1733. https://pubmed.ncbi.nlm.nih.gov/42848371/
- National Institutes of Health, Office of Dietary Supplements. (n.d.). Niacin: Health professional fact sheet. https://ods.od.nih.gov/factsheets/Niacin-HealthProfessional/
This article reports on recent health research and is for general information only — it isn’t medical advice and doesn’t replace your doctor, pharmacist, or another qualified professional. Study findings describe what researchers observed, not a promise of results, and nothing here claims any supplement can diagnose, treat, cure, or prevent a disease. These statements have not been evaluated by Health Canada. Check with a healthcare professional before starting any new supplement, especially if you’re pregnant, nursing, taking medication, or managing a health condition.
